

Mark L Warren

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/810549/publications.pdf>

Version: 2024-02-01

8
papers

5,089
citations

1307366
7
h-index

1588896
8
g-index

8
all docs

8
docs citations

8
times ranked

5029
citing authors

#	ARTICLE	IF	CITATIONS
1	Improved postprandial glucose control with ultra rapid lispro versus lispro with continuous subcutaneous insulin infusion in type 1 diabetes: <sc>PRONTO&Pump</sc>. Diabetes, Obesity and Metabolism, 2021, 23, 1552-1561.	2.2	25
2	Semaglutide improves health-related quality of life versus placebo when added to standard of care in patients with type 2 diabetes at high cardiovascular risk (<sc>SUSTAIN</sc> 6). Diabetes, Obesity and Metabolism, 2020, 22, 1339-1347.	2.2	18
3	Oral Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes. New England Journal of Medicine, 2019, 381, 841-851.	13.9	1,002
4	Patient-reported outcomes from a randomized, crossover trial comparing a pen injector with insulin degludec versus a pen injector with insulin glargine U100 in patients with type 2 diabetes. Current Medical Research and Opinion, 2019, 35, 1623-1629.	0.9	3
5	Semaglutide as a therapeutic option for elderly patients with type 2 diabetes: Pooled analysis of the SUSTAIN 1&5 trials. Diabetes, Obesity and Metabolism, 2018, 20, 2291-2297.	2.2	38
6	Semaglutide induces weight loss in subjects with type 2 diabetes regardless of baseline <sc>BMI</sc> or gastrointestinal adverse events in the SUSTAIN 1 to 5 trials. Diabetes, Obesity and Metabolism, 2018, 20, 2210-2219.	2.2	87
7	Insulin Degludec 200 Units/mL Is Associated With Lower Injection Frequency and Improved Patient-Reported Outcomes Compared With Insulin Glargine 100 Units/mL in Patients With Type 2 Diabetes Requiring High-Dose Insulin. Clinical Diabetes, 2017, 35, 90-95.	1.2	18
8	Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes. New England Journal of Medicine, 2016, 375, 1834-1844.	13.9	3,898